Meet & Greet the ONCOLOGY Board Members and Editorial Team at ASH 2018

Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

The ONCOLOGY team invites you to attend a meet and greet event with our team and members of our expert Advisory Board at the 60th American Society of Hematology (ASH) 2018 meeting in San Diego, California. Appetizers and drinks will be served!

Meet the following hematology/oncology experts:

  • Julie M. Vose, MD, MBA, FACP, FASCO
  • John Sweetenham, MD, FRCP
  • Stephen T. Rosen, MD

Event Details

Date: Saturday, December 1, 2018

Time: 2:00 PM to 3:00 PM

Location: Booth #3011 in the San Diego Convention Center Exhibit Hall
 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content
106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)

Reshma L. Mahtani, DO ;Diana Lüftner;Denise Wrobel;Dagmar Guth;Matthias Zaiss;Jürgen Terhaag;Mark-Oliver Zahn;Lidia Pervola-Griff;Andrea Distelrath;Rachel Würstlein;Jörg Thomalla;Klaus Apel;Natalija Deuerling;Timo Schinköthe;Corinne Vannier;Rupert Bartsch;Christian Jackisch;Volkmar Müller;Marcus Schmidt;Marija Balic;Gabriel Rinnerthaler;Urs Breitenstein;Khalil Zaman;Michael Schwitter;Nadia Harbeck, MD, PhD
April 10th 2025
Article
Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Key CAR T and Transplantation Presentations From The 2025 Tandem Meeting

Rahul Banerjee, MD, FACP;Shernan Holtan, MD
March 3rd 2025
Podcast

Shernan Holtan, MD, and Rahul Banerjee, MD, FACP, discussed various trials of significance shared as posters and presentations at the 2025 Tandem Meeting.

At baseline, 55% of patients achieved at least 6 metabolic equivalence tasks hours per week, 47% achieved it at timepoint 2, and 43% at timepoint 3.

Female AYA Cancer Survivors May Benefit From Increased Physical Activity

Ariana Pelosci
April 10th 2025
Article

The study found that older females with central nervous system tumors had significantly lower vigorous physical activity participation vs their counterparts.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Telehealth Groups May Improve the Social Lives of Young Cancer Populations

Tim Cortese
April 3rd 2025
Article

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.